Lindbrook Capital’s Minerva Neurosciences NERV Stock Holding History

Lindbrook Capital’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-250	Closed	-$11K	–	1501
2019 Q2	$11K	Buy	+250	New	+$12.5K	﹤0.01%	869

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Lindbrook Capital's NERV Position: Q3 2019 in Review

Lindbrook Capital sold out of Minerva Neurosciences (NERV) in Q3 2019, closing a stake of 250 shares — an estimated $11K sold.

Lindbrook Capital first reported a position in NERV in Q2 2019 and held it in 1 quarter. The position peaked at $11K in Q2 2019. 87 funds tracked by Wall St. Rank hold NERV as of Q3 2019.

Lindbrook Capital reported no remaining Minerva Neurosciences position as of Q3 2019 after selling out during the quarter.
Lindbrook Capital sold 250 Minerva Neurosciences shares in Q3 2019, an estimated $11K.
Lindbrook Capital first reported a position in Minerva Neurosciences in Q2 2019 and held it in 1 quarter.
Lindbrook Capital's Minerva Neurosciences position peaked at $11K in Q2 2019.
87 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2019.

Based on Lindbrook Capital's 13F filing for Q3 2019, filed 31 Oct 2019.